A detailed history of Concord Wealth Partners transactions in Organon & Co. stock. As of the latest transaction made, Concord Wealth Partners holds 1,035 shares of OGN stock, worth $15,245. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,035
Previous 1,070 3.27%
Holding current value
$15,245
Previous $22,000 13.64%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$18.65 - $23.03 $652 - $806
-35 Reduced 3.27%
1,035 $19,000
Q2 2024

Jul 31, 2024

SELL
$17.45 - $21.96 $139 - $175
-8 Reduced 0.74%
1,070 $22,000
Q1 2024

Apr 30, 2024

SELL
$13.78 - $18.8 $468 - $639
-34 Reduced 3.06%
1,078 $20,000
Q4 2023

Apr 30, 2024

BUY
$10.95 - $17.32 $21 - $34
2 Added 0.18%
1,112 $16,000
Q4 2023

Feb 05, 2024

BUY
$10.95 - $17.32 $21 - $34
2 Added 0.18%
1,112 $16,000
Q3 2023

Apr 30, 2024

SELL
$16.59 - $23.77 $33 - $47
-2 Reduced 0.18%
1,110 $19,000
Q3 2023

Oct 25, 2023

BUY
$16.59 - $23.77 $16,606 - $23,793
1,001 Added 918.35%
1,110 $19,000
Q2 2023

Aug 07, 2023

SELL
$19.27 - $24.63 $21,312 - $27,240
-1,106 Reduced 91.03%
109 $2,000
Q1 2023

Apr 26, 2023

SELL
$21.42 - $32.08 $1,456 - $2,181
-68 Reduced 5.3%
1,215 $28,000
Q4 2022

Jan 27, 2023

BUY
$23.31 - $28.61 $29,906 - $36,706
1,283 New
1,283 $35,000
Q2 2022

Aug 04, 2022

BUY
$31.66 - $38.9 $46,413 - $57,027
1,466 New
1,466 $49,000
Q1 2022

Apr 20, 2022

SELL
$30.45 - $39.36 $39,615 - $51,207
-1,301 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$28.67 - $37.13 $35,636 - $46,152
1,243 Added 2143.1%
1,301 $40,000
Q3 2021

Nov 09, 2021

SELL
$28.63 - $35.64 $601 - $748
-21 Reduced 26.58%
58 $2,000
Q2 2021

Jul 29, 2021

BUY
$28.45 - $38.0 $2,247 - $3,002
79 New
79 $2,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.75B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.